These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24166514)

  • 21. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
    Uetake H; Yasuno M; Ishiguro M; Kameoka S; Shimada Y; Takahashi K; Watanabe T; Muro K; Baba H; Yamamoto J; Mizunuma N; Tamagawa H; Mochizuki I; Kinugasa Y; Kikuchi T; Sugihara K
    Ann Surg Oncol; 2015 Mar; 22(3):908-15. PubMed ID: 25465375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cetuximab in metastatic colorectal cancer.
    Wolf I; Golan T; Shani A; Aderka D
    Lancet Oncol; 2010 Apr; 11(4):313-4; author reply 314. PubMed ID: 20359660
    [No Abstract]   [Full Text] [Related]  

  • 23. [Efficacy and safety of cetuximab+irinotecan for unresectable advanced or recurrent colorectal cancer].
    Soda H; Nemoto H; Akatsuka S; Arioka H; Shimada K; Ito T; Takinishi Y; Egawa M; Nagashima A; Kenmochi T; Sasaki T; Azuma T; Koizumi W; Hibi K
    Gan To Kagaku Ryoho; 2013 May; 40(5):605-8. PubMed ID: 23863582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases.
    Lam VW; Spiro C; Laurence JM; Johnston E; Hollands MJ; Pleass HC; Richardson AJ
    Ann Surg Oncol; 2012 Apr; 19(4):1292-301. PubMed ID: 21922338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncological management of unresectable liver metastases.
    Prenen H; Van Cutsem E
    Dig Dis; 2012; 30 Suppl 2():137-42. PubMed ID: 23207946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
    Modest DP; Stintzing S; Laubender RP; Neumann J; Jung A; Giessen C; Haas M; Aubele P; Schulz C; Boeck S; Stemmler HJ; Kirchner T; Heinemann V
    Anticancer Drugs; 2011 Oct; 22(9):913-8. PubMed ID: 21795973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab in metastatic colorectal cancer.
    Broadbridge VT; Karapetis CS; Price TJ
    Expert Rev Anticancer Ther; 2012 May; 12(5):555-65. PubMed ID: 22594891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
    Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
    Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
    Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
    Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].
    Yoda Y; Yoshino T; Kadowaki S; Bando H; Okano S; Fukushima H; Fuse N; Tahara M; Doi T; Ohtsu A
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1003-6. PubMed ID: 19542725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS status predicts response to cetuximab for metastatic colorectal cancer.
    McBride D
    ONS Connect; 2008 Aug; 23(8):25. PubMed ID: 18767573
    [No Abstract]   [Full Text] [Related]  

  • 33. Biomarkers and efficacy: are we nearly there yet?
    Russo A; Rizzo S
    Ann Oncol; 2011 Jul; 22(7):1469-1470. PubMed ID: 21551003
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.
    Baba K; Oshita A; Kohyama M; Inoue S; Kuroo Y; Yamaguchi T; Nakamura H; Sugiyama Y; Tazaki T; Sasaki M; Imamura Y; Daimaru Y; Ohdan H; Nakamitsu A
    World J Gastroenterol; 2015 Feb; 21(6):1982-8. PubMed ID: 25684967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.
    Lieberman R
    Am J Ther; 2012 Nov; 19(6):395-6. PubMed ID: 23011178
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
    Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
    World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
    Ku GY; Haaland BA; de Lima Lopes G
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
    Shitara K; Yokota T; Takahari D; Shibata T; Ura T; Komatsu Y; Yuki S; Yoshida M; Takiuchi H; Utsunomiya S; Yatabe Y; Muro K
    Jpn J Clin Oncol; 2010 Jul; 40(7):699-701. PubMed ID: 20304778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].
    Asai H; Shinozaki E; Nozaki A; Watanabe T; Suenaga M; Matuzaka S; Chin K; Mizunuma N; Yasukawa M; Hatake K
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1285-91. PubMed ID: 21829065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.